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Abstract
Background: Arteriovenous malformation of the vein of Galen with partial anomalous pulmonary venous return
can lead to a critically challenging condition associated with a high morbidity and mortality.
Case report: We report a case of a full term infant born with a vein of Gallen arteriovenous malformation
complicated by partial anomalous pulmonary venous return and congestive heart failure where B-type natriuretic
peptide was used as a vital tool in clinical assessment and treatment management.
Conclusions: Rapid diagnosis and treatment in infants with complex conditions such as this are imperative to
expedite appropriate treatments, preventing long term negative outcome.
Introduction
Vein of Galen arteriovenous malformations (VGAM)
account for less than 1% of the arteriovenous malforma-
tions which are estimated to be seen in only 2.5 out of
100,000 live births [1]. VGAM consists of a saccular
dilatation of the vein of Galen pooling blood shunted
directly from abnormally enlarged cerebral arteries and
often causing congestive heart failure (CHF), hypoxic
respiratory failure, and/or persistent pulmonary hyper-
tension of the newborn (PPHN).
Neonates born with VGAM who have complex car-
diac disorders as well can present with pulmonary
hypertension and/or CHF with additional management
challenges. Even when echocardiography is easily avail-
able, a non-invasive screening test such as B-type
natriuretic peptide (BNP) assay can be helpful in asses-
sing and managing CHF in patients presenting with
complex cardiopulmonary conditions.
BNP is secreted by myocytes primarily from the car-
diac ventricles and directly correlates with left
ventricular end diastolic pressure and wall stress. Moni-
toring of BNP in infants has proven to be a helpful non-
invasive diagnostic and management screening tool
[2,3]. While BNP assays have commonly been used to
assess CHF in adult patients, it has only recently been
used in neonates to differentiate cardiopulmonary dis-
eases and to monitor the clinical course of such diseases
with serial testing [3]. Infants with cardiovascular pro-
blems have significantly higher BNP levels (>550 pg/mL,
range 578-1,435) compared to infants with non-cardiac
problems that present with respiratory difficulties (mean
240 pg/ml, range 118-388) [4]. Healthy newborns tend
to achieve a steady BNP level by 60 hours of life, with
plasma concentrations highest on day of life (DOL) 0
(range approximately 56.7 +/- 49.6 pg/ml) and continu-
ously decreasing, reaching adult levels at 3 months of
age [5]. Past the neonatal period BNP levels should be
less than 100 and before four months of age average
around 21 pg/ml [6].
Cases of VGAM causing high output heart failure
complicated by PPHN are rare and complex. A current
literature review produced a few case reports on the
pathological basis of PPHN leading to fatalities [7,8],
rapid diagnostic imaging with ultrasound [9,10], and
minimally invasive surgical techniques [11]. Tan et al.
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lization for a neonate with uncomplicated VGAM and
heart failure [12]. However, this report presents the first
case study following serial BNP assays for management
of care in a neonate with VGAM with high output car-
diac failure complicated by partial anomalous pulmonary
venous return (PAPVR) with sinus venosus defect and
pulmonary hypertension.
Case presentation
This full-term female infant was born via spontaneous
vaginal delivery to a 32-year-old gravida 4, para 1 Cau-
casian mother at 40 and 5/7 weeks gestational age.
Mother’s medical history was unremarkable and preg-
nancy, labor, and delivery were uncomplicated. Birth
weight was 3330 grams. Apgar scores were 8 at 1 and 5
minutes of age, respectively. After delivery, oxygen
saturation was 93% and a 2/6 systolic murmur was
noted. During a workup for infection and respiratory
distress, oxygen saturation dropped to the 80s. Chest
radiography showed cardiomegaly. Cranial ultrasound
demonstrated a large vein of Galen arteriovenous mal-
formation with MRI with contrast confirming the diag-
nosis. Dopamine was initiated for treatment of
hypotension. Secondary to high flow AVM, this patient
was monitored closely for increased risk for heart failure
with serial BNP levels starting on DOL 4 when it was
found to be 2450 pg/mL. Echocardiogram on DOL 6
showed high-output heart failure and the combination
of a large sinus venosus ASD, with partial anomalous
pulmonary venous return (PAPVR; right upper pulmon-
ary vein to superior vena cava) and patent ductus arter-
iosus with pulmonary hypertension resulting in right to
left shunting. On DOL 9, a cerebral angiogram and Vein
of Galen aneurysm embolization were performed, redu-
c i n gt h ef l o wt o5 0 % .B N Pl e v e lo b t a i n e do nD O L1 0
was over 5000 pg/mL. Post-procedure, patient was
placed back on high frequency oscillator, inhaled nitric
oxide (iNO) was started at 20 parts per million, and
continued for 6 days. A second embolization treatment
that significantly reduced the flow was performed on
DOL 16. By DOL 21, BNP levels dropped to 426 pg/mL
with pulmonary hypertension still evident on echocar-
diogram. At 3 months of age, cardiac catheterization
showed significant blood return to the superior vena
cava, likely a result of the VGAM, and pulmonary
hypertension. Sildenafil was started and BNP levels
dropped below 100 pg/ml, as the patient’sc o n d i t i o n
improved. The patient was discharged home on oxygen,
diuretics and albuterol. She was readmitted 1 week later
for shortness of breath and tachypnea. BNP level was
218 pg/mL. She went into CHF quickly and required a
third coil embolization at 5.5 months of age after BNP
levels reached 2020 pg/mL.
By six months of age, the patient required placement
of a ventriculo-peritoneal shunt for hydrocephalus. She
had one other brief hospitalization for an upper respira-
tory infection but remained stable and has not been
hospitalized since. In no apparent respiratory or cardio-
vascular distress on DOL 295, her BNP level was 49 pg/
mL. Figure 1 displays serial changes in BNP levels
throughout her NICU and early pediatric hospital
course.
Developmental evaluation at 46 weeks of age identified
global functional developmental delays. However, at 22
months of age, her functional development was within
normal. At the time of her last brain scan, no obvious
shunting through the VGAM was detected.
Discussion
During the neonatal period, symptomatic infants with
VGAM present with severe cardiorespiratory alterations
at or shortly after birth, with the majority of cases (94%)
having high-output cardiac failure [13,14]. Severe PPHN
may be a complicating factor. Since newborns classically
develop CHF as a result of a tremendous left to right
shunting through the low resistance vascular bed of the
VGAM, symptomatic infants often appear cyanotic due
to right ventricular volume and pressure overload [10].
Echocardiography holds an essential role in estimating
ventricular function and shunting across the PDA and
atrial septum, right ventricles and pulmonary artery pres-
sures, and identifying associated cardiac conditions in
infants with VGAM [13]. In addition, echocardiography
may reveal reversal of aortic flow during diastole, also
known as a steal phenomenon that decreases peripheral
perfusion [10]. Cardiac failure and pulmonary hyperten-
sion are the most dramatic and challenging concerns for
medical stabilization of the symptomatic neonate. NO,
the most effective therapy for treating pulmonary hyper-
tension, has limited success in infants with VGAMs and
PPHN [10]. While optimal strategies are yet to be clearly
defined, diuretic and inotrope therapy may be successful
in helping deferral of endovascular treatment for these
patients. However, management of those diagnosed with
coexisting pulmonary hypertension is demanding and
warrants serial BNP tests to monitor the clinical course.
The endovascular treatment of a VGAM often
requires several successive procedures. Staged emboliza-
tion sessions initially aimed at controlling cardiac failure
help avoiding the occurrence of parenchymal bleedings
or massive venous thrombosis potentially endangering
the normal venous drainage. Monitoring beyond the
neonatal period includes checking for increased head
circumference, hydrocephalus, seizures, and develop-
mental delays. The etiology of often associated psycho-
motor disabilities derives from the cerebral steal
phenomenon [10].
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management have led to more favorable long term out-
comes [10,15]. A 30 month follow-up study reported
that 55% of their patients were functionally normal [15].
While the past mortality rate for this population was
close to 100% [16], more recent studies report 9-15%
mortality and little to no neuromorbidity in 61-66% of
survivors [17,18].
Rapid diagnosis and treatment in infants with complex
conditions such as this are imperative to expedite appro-
priate treatments, preventing long term negative out-
come. We speculate that including serial BNP levels in
the arnament of assessment tools may aid the neonatal
management and promote better outcomes in these
complex patients.
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